.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Colorcon
Medtronic
Cantor Fitzgerald
Julphar
Novartis
Teva
Baxter
Covington

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,735,372

« Back to Dashboard

Which drugs does patent 8,735,372 protect, and when does it expire?


Patent 8,735,372 protects HARVONI, EPCLUSA, and VOSEVI, and is included in three NDAs.

This patent has fifty-nine patent family members in thirty-three countries.

Summary for Patent: 8,735,372

Title:Nucleoside phosphoramidate prodrugs
Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001## Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Inventor(s): Du; Jinfa (Redwood City, CA), Nagarathnam; Dhanapalan (Bethany, CT), Sofia; Michael Joseph (Doylestown, PA), Wang; Peiyuan (Totowa, NJ)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:14/057,675
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences Inc
HARVONI
ledipasvir; sofosbuvir
TABLET;ORAL205834-001Oct 10, 2014RXYesYes► Subscribe► Subscribe FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc
EPCLUSA
sofosbuvir; velpatasvir
TABLET;ORAL208341-001Jun 28, 2016RXYesYes► Subscribe► Subscribe FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc
VOSEVI
sofosbuvir; velpatasvir; voxilaprevir
TABLET;ORAL209195-001Jul 18, 2017RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,735,372

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,964,580Nucleoside phosphoramidate prodrugs► Subscribe
8,906,880Nucleoside phosphoramidate prodrugs► Subscribe
8,957,046Nucleoside phosphoramidate prodrugs► Subscribe
9,585,906Nucleoside phosphoramidate prodrugs► Subscribe
9,085,573Nucleoside phosphoramidate prodrugs► Subscribe
8,580,765Nucleoside phosphoramidate prodrugs► Subscribe
8,334,270Nucleoside phosphoramidate prodrugs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,735,372

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI357332► Subscribe
Taiwan200904453► Subscribe
Slovenia2203462► Subscribe
Singapore2014011704► Subscribe
Singapore179445► Subscribe
Russian Federation2012152811► Subscribe
Russian Federation2478104► Subscribe
Russian Federation2009139968► Subscribe
Portugal2203462► Subscribe
Philippines12014502771► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Healthtrust
McKinsey
Fish and Richardson
Express Scripts
Fuji
Deloitte
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot